论文部分内容阅读
目的:探讨帕妥珠单抗治疗人表皮生长因子受体2(HER2)阳性乳腺癌患者的疗效及对血清结合素-4(nectin-4)与胸苷激酶1(TK-1)表达的影响。方法:回顾性分析2014年6月至2016年12月在北京市隆福医院治疗的110例HER2阳性乳腺癌患者的临床资料，按治疗方法分为观察组和对照组，各55例。对照组给予多西他赛联合铂类(TP)新辅助化疗，观察组给予TP新辅助化疗联合帕妥珠单抗治疗，均治疗18周后观察两组患者的治疗效果，观察治疗后患者血清肿瘤标志物[糖类抗原125(CA125)、糖类抗原153(CA153)、糖类抗原199(CA199)]、免疫功能、nectin-4与TK-1水平以及不良反应。结果:观察组的总有效率为83.64%(46/55)，显著高于对照组[58.18%(32/55)]，差异有统计学意义(n P<0.05)；治疗后两组患者的CA125、CA153、CA199水平均下降，且观察组下降更显著，差异有统计学意义(n P0.05)；治疗后两组患者的nectin-4、TK-1水平均下降，且观察组下降更明显，差异有统计学意义(n P0.05)；2年随访，观察组病死率为3.64%(2/55)，对照组病死率为10.91%(6/55)，观察组病死率显著低于对照组，差异有统计学意义(n P<0.05)。n 结论:帕妥珠单抗、TP方案新辅助化疗治疗HER2阳性乳腺癌患者的效果较好，可有效地抑制肿瘤组织的生长，降低血清肿瘤标志物和nectin-4、TK-1水平，对患者免疫应答反应影响较小，不良反应较少，且病死率较低，在临床上可广泛使用。“,”Objective:To investigate the effect of pertuzumab in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients and its effect on the expression of serum nectin-4 and thymidine kinase 1 (TK-1).Methods:110 HER2 positive breast cancer patients treated in Longfu Hospital of Beijing from June 2014 to December 2016 were selected and divided into observation group and control group according to treatment method, 55 cases in each group.The control group was given docetaxel combined with platinum (TP) neoadjuvant chemotherapy, and the observation group was given TP neoadjuvant chemotherapy combined with paltuzumab. After 18 weeks of treatment, the therapeutic effect, serum tumor markers [carbohydrate antigen (CA), CA153 and CA199], immune function, levels of nectin-4 and TK-1 and adverse reactions were observed.Results:The total effective rate of the observation group was 83.64%(46/55), which was significantly higher than that of the control group 58.18%(32/55), with statistically significant difference (n P<0.05). After treatment, the levels of CA125, CA153 and CA199 in the two groups were decreased, and the difference was significant in the observation group (n P0.05). After treatment, the levels of serum nectin-4 and TK-1 decreased in both groups, and the the decrease in the observation group was significant (n P0.05). Two years follow-up showed that the mortality of the observation group was 3.64%(2/55), and that of the control group was 10.91%(6/55). The mortality of the group was significantly lower than that of the control group (n P<0.05).n Conclusions:Pertuzumab combined with TP neoadjuvant chemotherapy has better effect on HER2 positive breast cancer patients, it can effectively inhibit the growth of tumor tissues, reduce the level of tumor markers and the level of nectin-4 and TK-1, and has less influence on the immune response of patients with fewer adverse reactions and lower mortality rate.